led name

names	1
Deed	

		Attorne	y Docket No.		Application No.				
INFOR	INFORMATION DISCLOSURE OF FATION			056291-5241			10/573,090		
	(U	se several sheets if neo	essary)	Applicants: H	ENNEQUIN e	t al.			
		PTO Form 1449 April 20, 2007	<b>3</b>	Filing Date:	March 15, 20	006	Group	Art Unit <b>XIXX</b> 1624	
			U.S. PA	TENT DOCUM	IENTS				
Initial	Ι -	Document No.	Date	y	ame	Class	Sub-Class	Filing Date	
				<del></del>					
		<del></del>					f		
					· . · · · · · · · · · · · · · · · · · ·				
			· · · · · · · · · · · · · · · · · · ·				1		
	<b>.</b>	*	FORFICN	PATENT DOC	IIMENTS		<del></del>		
	Ι	Document No.	Date		untry	Class	Sub-Class	Translation	
/T.N./	1.	DE 10040527	February 28, 2002		many	Ciuss	040-01433	Claims	
/T N /	2.	WO 00/09481	February 24, 2000		IPO			Claims	
/T.N./	3.	WO 02/062767	August 15, 2002		TPO		1	Claims	
<del>/ I - I V -/</del>	-						<del>                                     </del>		
							† · · · · · · · · · · · · · · · · · · ·		
	<u> </u>	OTHER DO	OCUMENTS (Includ	ing Author Tit	la Data Part	inent Pac	ies etc.)		
	4.	Ballard et al. "Inhibite						uted	
/T.N./	7.	anilinoquinazolines de							
	5.	Ballard et al. "5-Subst							
/T.N./	-	tyrosine kinase" Bioor							
	6.	Ballard et al. "Inhibito	ors of epidermal growt	h factor receptor	r tyrosine kina	se: optimi	isation of po	tency and in vivo	
/T.N./		pharmacokinetics" Bio				•	•	•	
/T.N./	7		nthesis of 7-amino an			nination o	f the quinazo	oline core" Tetrahedron	
/T.N./	8.	Harris et al. "Selective		hydroxyguinazo	line" Tetraheo	iron letter	s 46(45):771	5-7719 (2005).	
/ L.IN./	9.	Hennequin et al. "Nov							
/T.N./	· .	relationship of a series 16(10):2672-2676 (20	of potent, orally activ						
	ļ								
					<del></del>				
	<del> </del>	<del></del>	<del></del>						
			· · · · · · · · · · · · · · · · · · ·						
	<del> </del>								
	<del></del>				· · ·		<del></del>		
		<del></del>	<del></del>	····			<del></del>	<del></del>	
	<del>                                     </del>	<del></del>				<del></del>			
							-		
_	<del>                                     </del>								
<del></del>			<del> </del>	,					
	<u> </u>						<del></del>		
-									
Examiner	1	/Tamthom Truong/	Date C	onsidered	02/10	)/2009			
		l if reference considere not considered. Includ					draw line th	rough citation if not in	



#### Application No. Attorney Docket No. 10/573,090 056291-5241 INFORMATION DISCLOSURE CHATLON (Use several sheets if necessar Applicants: HENNEQUIN et al. 1624 PTO Form 1449 Filing Date: March 15, 2006 Group Art Unix Lingssigned September 1, 2006 SIDERED EXCEPT WHERE LINED THROUGH. /T.N./ ALL REFER S. PATENT DOCUMENTS Name Class Sub-Class Filing Date Initial Document No. Date Himmelsbach et al. 514 217.06 August 23, 2001 April 25, 2002 1. US 20020049197 514 266.2 August 22, 2001 June 27, 2002 Himmelsbach et al. 2. US 20020082270 514 266.24 August 22, 2001 US 20020082271 Himmelsbach et al. 3. June 27, 2002 September 12, 2002 Mishani et al. 600 431 March 12, 2001 4. US 20020128553 514 266.4 December 10, 2001 November 14, 2002 Himmelsbach et al. 5. US 20020169180 514 December 17, 2001 234.5 6. US 20020173509 November 21, 2002 Himmelsbach et al. 266.2 August 23, 2001 7. November 28, 2002 Himmelsbach et al. 514 US 20020177601 January 29, 2003 514 266.22 8. US 20030149062 August 7, 2003 Jung et al. 514 234.2 February 7, 2003 9. US 20030158196 August 21, 2003 Jung et al. May 8, 2003 514 233.8 Singer et al. 10. US 20030225079 December 4, 2003 266.4 April 17, 2003 514 11. US 20040044014 March 4, 2004 Himmelsbach et al. March 11, 2004 Himmelsbach et al. 514 266.2 March 27, 2003 12. US 20040048880 February 24, 2004 224.2 September 9, 2004 514 13. US 20040176361 Fujio et al. July 7, 2005 Suzuki et al. 514 264.11 June 3, 2003 14. US 20050148607 514 266.22 June 1, 2004 July 28, 2005 Bradbury et al. 15. US 20050165035 April 7, 1972 514 266.21 16. US 3,812,257 May 21, 1974 Yamamoto April 26, 1974 US 3,971,783 July 27, 1976 Barnish et al. 514 284 17. 514 266.22 October 12, 1979 18. US 4,335,127 June 15, 1982 Vandenberk et al. 514 319 February 17, 1988 19. US 4,921,863 May 1, 1990 Sugimoto et al. 514 266.3 July 19, 1993 20. US 5,411,963 May 2, 1995 Dreikorn et al. 514 234.5 August 2, 1994 21. October 10, 1995 Barker US 5,457,105 234.5 June 15, 1995 22 US 5,616,582 Barker 514 April 1, 1997 514 266.4 May 28, 1996 23 Schnur et al. US 5,747,498 May 5, 1998 US 5,770,599 June 23, 1998 Gibson 514 228.2 April 26, 1996 24. November 15, 1996 October 6, 1998 Kim et al. 514 326 25. US 5.817.678 October 5, 1998 235.5 514 26. US 6,127,366 October 3, 2000 Kim et al. 266.4 November 19, 1999 27. US 6,177,433 January 23, 2001 Uckun et al. 514 249 March 29, 1999 Ries et al. 514 28. US 6,200,976 March 13, 2001 29. US 6,297,258 October 2, 2001 Wissner et al. 514 313 August 1, 2000 30. US 6,313,127 November 6, 2001 Waterson et al. 514 253.01 July 31, 1998 April 1, 2003 514 340 November 30, 2000 31. US 6,541,491 Davies et al. 424 1.81 March 12, 2001 32. US 6,562,319 May 13, 2003 Mishani et al. 514 252.14 August 23, 2001 Himmelsbach et al. 33. US 6,617,329 September 9, 2003 233.5 August 15, 2001 34. US 6,653,305 November 25, 2003 Himmelsbach et al. 514 REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /T.N./ FOREIGN PATENT DOCUMENTS Sub-Class Translation Document No. Date Country Class

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

Examiner /Tamthom Truong/ Date Considered

05/26/2009

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

#### Attorney Docket No. Application No. INFORMATION DISCLOSURE CITATION 056291-5241 10/573,090 (Use several sheets if necessary) Applicants: HENNEQUIN et al. PTO Form 1449 September 1, 2006 Filing Date: March 15, 2006 Group Art Unit: Whas in hear ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /T.N./ **U.S. PATENT DOCUMENTS** Initial Document No. Date Class Name Sub-Class Filing Date ī. US 20020049197 Himmelsbach et al. April 25, 2002 514 217.06 August 23, 2001 2. US 20020082270 June 27, 2002 Himmelsbach et al. 514 266.2 August 22, 2001 3. US 20020082271 June 27, 2002 Himmelsbach et al. 514 266.24 August 22, 2001 4. US 20020128553 September 12, 2002 Mishani et al. 600 March 12, 2001 431 5. US 20020169180 November 14, 2002 Himmelsbach et al. 514 266.4 December 10, 2001 6. US 20020173509 November 21, 2002 Himmelsbach et al. 514 234.5 December 17, 2001 7. US 20020177601 November 28, 2002 Himmelsbach et al. August 23, 2001 514 266.2 8. US 20030149062 August 7, 2003 Jung et al. 514 266.22 January 29, 2003 9. US 20030158196 August 21, 2003 Jung et al. 514 234.2 February 7, 2003 10. US 20030225079 December 4, 2003 Singer et al. 514 233.8 May 8, 2003 11. US 20040044014 March 4, 2004 Himmelsbach et al. 514 266.4 April 17, 2003 12. US 20040048880 March 11, 2004 Himmelsbach et al. 514 266.2 March 27, 2003 13. US 20040176361 September 9, 2004 Fujio et al. 514 224.2 February 24, 2004 14. US 20050148607 July 7, 2005 Suzuki et al. 514 264.11 June 3, 2003 15. US 20050165035 July 28, 2005 Bradbury et al. 514 266.22 June 1, 2004 16. US 3,812,257 May 21, 1974 Yamamoto 514 266.21 April 7, 1972 17. US 3,971,783 July 27, 1976 Barnish et al. 514 284 April 26, 1974 18. US 4,335,127 June 15, 1982 Vandenberk et al. 514 266.22 October 12, 1979 19 US 4,921,863 May 1, 1990 Sugimoto et al. 514 319 February 17, 1988 20. May 2, 1995 US 5.411.963 Dreikorn et al. 514 266.3 July 19, 1993 21. US 5,457,105 October 10, 1995 Barker 514 234.5 August 2, 1994 April 1, 1997 22. US 5,616,582 Barker 514 234.5 June 15, 1995 23. US 5,747,498 May 5, 1998 Schnur et al. 514 266.4 May 28, 1996 24. US 5,770,599 June 23, 1998 Gibson 514 228.2 April 26, 1996 25. US 5,817,678 October 6, 1998 Kim et al. 514 326 November 15, 1996 26. US 6,127,366 October 3, 2000 Kim et al. 514 235.5 October 5, 1998 27 US 6,177,433 January 23, 2001 Uckun et al. 514 266.4 November 19, 1999 28. US 6,200,976 March 13, 2001 Ries et al. 514 249 March 29, 1999 29. US 6,297,258 October 2, 2001 Wissner et al. 514 313 August 1, 2000 30. US 6,313,127 November 6, 2001 Waterson et al. 514 253.01 July 31, 1998 31. US 6,541,491 April 1, 2003 Davies et al. 514 340 November 30, 2000 32. US 6,562,319 May 13, 2003 Mishani et al. 424 1.81 March 12, 2001 33. US 6,617,329 September 9, 2003 Himmelsbach et al. 514 252.14 August 23, 2001 34. US 6,653,305 November 25, 2003 Himmelsbach et al. 514 233.5 August 15, 2001 <del>ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH</del> /T N FOREIGN PATENT DOCUMENTS Document No. Date Country Class Sub-Class Translation OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.) Examiner /Tamthom Truong/ Date Considered 05/26/2009 Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

				Attorney Doo	ket No		plication No.	
INFO		TION DISCLOSU		056291-5		Application No. 10/5 <b>73,090</b>		
	(U	se several sheets if ne	cessary)	Applicants: HENNEQUIN et al.				
		PTO Form 1449				_	1624	
		September 1, 200		Filing Date: Mar	ch 15, 2006	Group Ai	t Unit: XIMXSKIK KOKIX	
	/		CONSIDERED EX U.S. PA	(CEPT WHERE LIF <b>TENT DOCUMENT</b>	NED THROUG S	H. /I.N./		
Initial	<u> </u>	Document No.	Date	Name	Class	Sub-Class	Filing Date	
<u> </u>	35.	US 6,656,946	December 2, 2003			266.4	August 22, 2001	
	36.	US 6,740,651	May 25, 2004	Himmelsbach		228.8	August 22, 2001	
	37.	US 6,972,288	December 6, 2003	Himmelsbach	et al. 514	234.8	February 6, 2002	
		L DEFEDENCES (	ANGINEDED EVO	<del></del>	D TUDOUCH	<u></u>		
	AL	L REFERENCES (	ONSIDERED EXC FOREIGN	EPT WHERE LINE PATENT DOCUME		/ 1 .IN./		
		Document No.	Date	Country		Sub-Class	Translation	
	38.	DE 19908567	August 31, 2000				US 6,972,288	
	39.	EP 0 288 563	May 11, 1994	EPO				
	40.	EP 0 566 226	November 8, 1995	EPO EPO		1	······································	
	41.	EP 0 585 371	April 17, 2002	EPO				
	42.	EP 0 669 324	August 30, 1995	EPO				
	43.	EP 0 837 063	April 22, 1998	EPO				
	44.	EP 1 044 969	October 18, 2000	EPO			<del></del>	
	45.	EP 1 230 919	August 14, 2002	EPO				
	46.	EP 1 369 418	December 10, 200	EPO				
	47.	EP 1 548 008	June 29, 2005	EPO				
	48.	GB 2,295,387	May 29, 1996	United Kingd	lom			
	49.	WO 88/02365	April 7, 1988	WIPO			US 4,921,863	
	50.	WO 92/20642	November 26, 1992	2 WIPO				
	51.	WO 95/00146	January 5, 1995	WIPO				
	52.	WO 95/15758	June 15, 1995	WIPO				
	53.	WO 96/09294	March 28, 1996	WIPO				
	54.	WO 96/30347	October 3, 1996	WIPO				
- ·	55.	WO 96/33977	October 31, 1996	WIPO				
	56.	WO 96/33978	October 31, 1996	WIPO				
	57.	WO 96/33979	October 31, 1996	WIPO				
	58.	WO 96/33980	October 31, 1996	WIPO				
	59. 60.	WO 96/33981	October 31, 1996	WIPO				
	61.	WO 96/39145	December 12, 1996					
	62.	WO 97/03069 WO 97/06138	January 30, 1997	WIPO				
	63.	WO 97/18813	February 20, 1997	WIPO	·			
	64.	WO 97/22596	May 29, 1997	WIPO		<b>_</b>		
	65.	WO 97/28128	June 26, 1997	WIPO		<b></b>		
	66.	WO 97/30034	August 7, 1997	WIPO				
	67.	WO 97/30034 WO 97/30035	August 21, 1997 August 21, 1997	WIPO				
	68.	WO 97/30044	August 21, 1997  August 21, 1997	WIPO		<u> </u>		
			NSIDERED EXCEP	TWHERE TIMEN	THROHGH /T	N /   -		
	<u> </u>		CUMENTS (Includia	<del></del>		<u> </u>		
Examiner								
-vanimici		/Tamthom Truo	Date Co	nsidered	05/26/2009			
	xaminer: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in							
onformance	e and no	ot considered. Include	copy of this form with	on is in conformance v	with MPEP 609;	draw line thro	ough citation if not in	
		. Jonatacica, menude	copy or this form with	i next communication	to applicant.			

names

Applicants: HENNEQUIN et al.	INFOI	RMA'	TION DISCLOSU	JRE CITATION		Attorney Docket No. 056291-5241			pplication No. 10/573,090	
U.S. PATENT DOCUMENTS   U.S. PATENT DOCUMENTS   Initial   Document No. Date   Name   Class   Sub-Class   Filing Date						plicants: HENNEQUIN	et al.			
Initial   Document No.   Date   Name   Class   Sub-Class   Filing Date	1		- · · · · · · ·							
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH.   T.N.	<del></del>		September 1, 2006	6	<u></u> /	Filing Date: March 15, 2	<u> 2006  </u>	Group Ar	rt Unit: Unassigned	
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH.   T.N.	l	-		U.S. <u>P</u> A	ATE <u>N</u>	T DOCUMENTS				
AL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /T.N./  POREIGN PATENT DOCUMENTS  Document No. Date Country Class Sub-Class Translation  137. WO 03/101491 December 11, 2003 WIPO US 20050148607  138. WO 2004/0054718 August 5, 2004 WIPO 139. WO 2004/0054718 August 5, 2004 WIPO 140. WO 2004/096226 November 11, 2005 WIPO 141. WO 2005/03098 February 17, 2005 WIPO 142. WO 2005/026155 March 24, 2005 WIPO 143. WO 2005/026156 March 24, 2005 WIPO 144. WO 2005/030757 April 7, 2005 WIPO 144. WO 2005/030757 April 7, 2005 WIPO 145. WO 2005/030758 April 7, 2005 WIPO 146. WO 2005/03759 August 18, 2005 WIPO 147. Gaul et al. "Discovery and Biological Evaluation of Potent Dual Erb-P2/GFR tyrosine Kinase Inhibitors of thiazolylquinazolines" Bioorganic & Medicinal Chemistry Letters 13: 637-640 (2003). 148. Hennequin et al. "Design and structure activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors" Journal Of Medicinal Chemistry 42:5369-5389 (1999) 149. Hennequin et al. "Posign and structure activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors" Journal Of Medicinal Chemistry 42:5369-5389 (1999) 149. Hennequin et al. "Tyrosine kinase Inhibitors. 17. Irreversible Inhibitors" Journal Of Medicinal Chemistry 42:5369-5389 (1999) 150. Smaill et al. "Tyrosine kinase Inhibitors. 17. Irreversible Inhibitors" Journal Of Medicinal Chemistry 43:6(6):1300 151. Stamos et al. "Structure of the Epidermal Growth Factor Receptor: 4-(phenylaminoloquinazoline thiabitor." J. Biol. Chem. 277(48):44265-46272 (2002) 152. Traxler et al. "Tyrosine kinase inhibitors in cancer treatment (Part II)" Exp. Opin. Ther. Patents 7(6):571-588 (1997). 153. Traxler et al. "Frotein tyrosine kinase inhibitors in cancer treatment (Part II)" Exp. Opin. Ther. Patents 8(12):1599-1625 (1998). 154. Traxler et al. "Frotein tyrosine kinase inhibitors in cancer treatment (Part II)" Exp. Opin. Ther. Patents 8(12):1599-1625 (1998). 155. Verm et al. "Georgia kinase inhibitors in cancer treatment (Part II)" Exp.	Initial		Document No.				Class	Sub-Class	Filing Date	
Document No.   Date   Country   Class   Sub-Class   Translation	<del></del>	<u> </u>								
Document No.   Date   Country   Class   Sub-Class   Translation		+	-	-		<del> </del>	<del> </del>	+		
Document No.   Date   Country   Class   Sub-Class   Translation		+	- TEEDENOED	Tarana Ev			+		<del> </del>	
Document No.   Date   Country   Class   Sub-Class   Translation		<del>1</del>	LL REFERENCES "	CONSIDERED EX	<del>CE+</del>	T WHERE LINED IT!	ROUGH	<u>.+/ .N./</u>	<u> </u>	
Document No.   Date   Country   Class   Sub-Class   Translation	l				PAT		· .		<u></u>	
137. WO 03/101491 December 11, 2003 WIPO US 20050148607  138. WO 2004/006846 January 22, 2004 WIPO  140. WO 2004/0068218 August 5, 2004 WIPO  140. WO 2004/096226 November 11, 2004 WIPO  141. WO 2005/032615 Pebruary 17, 2005 WIPO  142. WO 2005/026156 March 24, 2005 WIPO  143. WO 2005/026157 March 24, 2005 WIPO  144. WO 2005/030757 April 7, 2005 WIPO  145. WO 2005/030757 April 7, 2005 WIPO  146. WO 2005/030765 April 7, 2005 WIPO  147. Gaul et al. "Discovery and Biological Evaluation of Potent Dual ErB-2/EGFR tyrosine Kinase Inhibitors: 6-thiazolylquinazolines" Bioorganic & Medicinal Chemistry Letters 13: 637-640 (2003).  148. Hennequin et al. "Discovery and Biological Evaluation of Potent Dual ErB-2/EGFR tyrosine Kinase Inhibitors: Journal of Medicinal Chemistry 42:5369-5389 (1999).  149. Hennequin et al. "Discovery in december 24:5369-5389 (1999).  149. Hennequin et al. "Discovery in december 24:5369-5389 (1999).  149. Hennequin et al. "Overland Chemistry 42:5369-5389 (1999).  149. Hennequin et al. "Overland Chemistry 42:5369-5389 (1999).  150. Smaill et al. "Tyrosine kinase Inhibitors. 17. Irreversible Inhibitors" Journal Of Medicinal Chemistry 45(6):1300 (1312 (2002).  150. Smaill et al. "Tyrosine kinase Inhibitors. 17. Irreversible Inhibitors" Journal Of Medicinal Chemistry 43(7):1380-1397 (2000).  151. Stamos et al. "Structure of the Epidermal Growth Factor Receptor Kinase Domain Alone and in Complex with a 4-Anilinoquinazoline Inhibitor'. J. Biol. Chem. 277(48).46265-46272 (2002).  152. Traxler et al. "Tyrosine kinase inhibitors in cancer treatment (Part II)" Exp. Opin. Ther. Patents 7(6):571-588 (1997).  153. Traxler et al. "Tyrosine kinase inhibitors in cancer treatment (Part II)" Exp. Opin. Ther. Patents 7(6):571-588 (1997).  154. Tsou et al. "Geoten tyrosine kinase inhibitors in cancer treatment (Part II)" Exp. Opin. Ther. Patents 7(6):571-588 (1997).  155. Verma et al. "Tyrosine kinase inhibitors in cancer treatment (Part II)" Exp. Opin. Ther. Patents 8(12):1599-1625 (1998).  155. Verma et al. "Design				Date		Country	Class	Sub-Class		
139. WO 2004/064718 August 5, 2004 WIPO 140. WO 2004/06226 November 11, 2004 WIPO 141. WO 2005/0319398 February 17, 2005 WIPO 142. WO 2005/026157 March 24, 2005 WIPO 143. WO 2005/026157 March 24, 2005 WIPO 144. WO 2005/030757 April 7, 2005 WIPO 145. WO 2005/030757 April 7, 2005 WIPO 146. WO 2005/030765 April 7, 2005 WIPO 147. WIPO 148. WO 2005/030765 April 7, 2005 WIPO 149. WIPO 140. WO 2005/030765 April 7, 2005 WIPO 141. WO 2005/030765 April 7, 2005 WIPO 142. WO 2005/030765 April 7, 2005 WIPO 143. WO 2005/05439 August 18, 2005 WIPO 144. WO 2005/075439 August 18, 2005 WIPO 145. WIPO 146. WO 2005/075439 August 18, 2005 WIPO 147. Gaul et al. "Discovery and Biological Evaluation of Potent Dual Erib-2/EGFR tyrosine Kinase Inhibitors:6-thiazolylquinazolines" Bioorganic & Medicinal Chemistry Letters 13: 637-640 (2003). 148. Hennequin et al. "Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors" Journal Of Medicinal Chemistry 42:369-3389 (1999). 149. Hennequin et al. "Novel 4-anilinoquinazolines with C-7 basic side chains: Design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors" Journal Of Medicinal Chemistry 43(6):130(1312 (2002). 150. Smaill et al. "Tyrosine kinase Inhibitors. 17. Irreversible Inhibitors of the Epidermal Growth Factor Receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)quinazoline- sare treatment (Part II)" Exp. Opin. Ther. Patents 7(6):571-588 (1997). 151. Stamos et al. "Structure of the Epidermal Growth Factor Receptor Kinase Domain Alone and in Complex with a 4-Anilinoquinazoline Inhibitor in cancer treatment" Exp. Opin. Ther. Patents 8(12):1599-1625 (1998). 152. Traxler et al. "Tyrosine kinase inhibitors in cancer treatment" Exp. Opin. Ther. Patents 8(12):1599-1625 (1998). 153. Traxler et al. "Tyrosine kinase inhibitors in cancer treatment (Part II)" Exp. Opin. Ther. Patents 8(12):1599-1625 (1998). 154. Tsou et al. "Gesupto Additional Chemistry 43(7):1380-1397 (2000). 15	<del></del>					WIPO				
140. WO 2003/096226 November 11, 2004 WIPO  141. WO 2005/013998 February 17, 2005 WIPO  142. WO 2005/026156 March 24, 2005 WIPO  143. WO 2005/026157 March 24, 2005 WIPO  144. WO 2005/030765 April 7, 2005 WIPO  145. WO 2005/030765 April 7, 2005 WIPO  146. WO 2005/030765 April 7, 2005 WIPO  147. WO 2005/030765 April 7, 2005 WIPO  148. WO 2005/030765 April 7, 2005 WIPO  ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /T.N./  OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)  147. Gaul et al. "Discovery and Biological Evaluation of Potent Dual Erb-2/EGFR tyrosine Kinase Inhibitors:6-thiazolylquinazolines" Bioorganic & Medicinal Chemistry Letters 13: 637-640 (2003) .  148. Hennequin et al. "Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors" Journal of Medicinal Chemistry 45(56):4598 (1999).  149. Hennequin et al. "Novel 4-anilinoquinazolines with C-7 basic side chains: Design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors" Journal of Medicinal Chemistry 45(6):130(1312 (2002) .  150. Smaill et al. "Tyrosine kinase Inhibitors. 17. Irreversible Inhibitors of the Epidermal Growth Factor Receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino0pyrido(3),2-d)pyrimidine-6-acrylamides bearing additional solubilizin function" Journal of Medicinal Chemistry 43(7):1380-1397 (2000).  151. Stamos et al. "Structure of the Epidermal Growth Factor Receptor Kinase Domain Alone and in Complex with a 4-Anilinoquinazoline inhibitors in cancer treatment" Exp. Opin. Ther. Patents 7(6):571-588 (1997), 153. Traxler et al. "Tyrosine kinase inhibitors in cancer treatment (Part II)" Exp. Opin. Ther. Patents 8(12):1599-1625 (1998).  154. Tsou et al. "Gesup of EGFR kinase inhibitors: a ligand-based approach and its confirmation with structure-based studies" Bioorg Med Chem. 11(21):4643-4653 (2003)	·——									
141. WO 2005/026156 March 24, 2005 WIPO 142. WO 2005/026157 March 24, 2005 WIPO 143. WO 2005/026157 March 24, 2005 WIPO 144. WO 2005/030757 April 7, 2005 WIPO 145. WO 2005/030757 April 7, 2005 WIPO 146. WO 2005/030765 April 7, 2005 WIPO 147. WO 2005/030765 April 7, 2005 WIPO 148. WO 2005/03519 August 18, 2005 WIPO 149. WIPO 140. WIPO 141. Gaul et al. "Discovery and Biological Evaluation of Potent Dual ErB-2/EGFR tyrosine Kinase Inhibitors:6-thiazolylquinazolines" Bioorganic & Medicinal Chemistry Letters 13: 637-640 (2003). 148. Hennequin et al. "Discovery and Biological Evaluation of Potent Dual ErB-2/EGFR tyrosine Kinase Inhibitors:6-thiazolylquinazolines Bioorganic & Medicinal Chemistry Letters 13: 637-640 (2003). 148. Hennequin et al. "Biogran and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors" Journal Of Medicinal Chemistry 42:5369-5389 (1999). 149. Hennequin et al. "Novel 4-anilinoquinazolines with C-7 basic side chains: Design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors" Journal Of Medicinal Chemistry 43(56):130(1312 (2002). 150. Smaill et al. "Tyrosine kinase Inhibitors. 17. Irreversible Inhibitors of the Epidermal Growth Factor Receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)dpyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizin function" Journal of Medicinal Chemistry 43(7):1380-1397 (2000). 151. Stamos et al. "Structure of the Epidermal Growth Factor Receptor Kinase Domain Alone and in Complex with a 4-Anilinoquinazoline Inhibitor" J. Biol. Chem. 277(48):46265-46272 (2002). 152. Traxler et al. "Protein tyrosine kinase inhibitors in cancer treatment" Exp. Opin. Ther. Patents 8(12):1599-1625 (1998). 153. Traxler et al. "Frotein tyrosine kinase inhibitors in cancer treatment" Exp. Opin. Ther. Patents 8(12):1599-1625 (1998). 154. Tsou et al. "G-Substituted-4-(3-bromophenylamino)quinazolines as Putative Irreversible Inhibitors of the Epidermal Growth Factor Recep	<del></del>									
142. WO 2005/026156 March 24, 2005 WIPO 143. WO 2005/026157 April 7, 2005 WIPO 144. WO 2005/030757 April 7, 2005 WIPO 145. WO 2005/030765 April 7, 2005 WIPO 146. WO 2005/030765 April 7, 2005 WIPO 147. WO 2005/030765 April 7, 2005 WIPO 148. WO 2005/0376439 August 18, 2005 WIPO 149. ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /T.N./ OTHER DOCUMENTS (Including Author, Title, Date, Pertiner Pages, etc.) 147. Gaul et al. "Discovery and Biological Evaluation of Potent Dual ErB-2/EGFR tyrosine Kinase Inhibitors" Biograpic & Medicinal Chemistry Letters 13: 637-640 (2003). 148. Hennequin et al. "Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors" Journal Of Medicinal Chemistry 42:3369-5389 (1999). 149. Hennequin et al. "Novel 4-anilinoquinazolines with C-7 basic side chains: Design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors" Journal Of Medicinal Chemistry 42:3369-5389 (1999). 150. Smaill et al. "Tyrosine kinase Inhibitors. 17. Irreversible Inhibitors of the Epidermal Growth Factor Receptor: 4- (phenylamino)quinazoline- and 4-(phenylaminotpyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizin, function" Journal of Medicinal Chemistry 43(7):1380-1397 (2000). 151. Stamos et al. "Structure of the Epidermal Growth Factor Receptor Kinase Domain Alone and in Complex with a 4- Anilinoquinazoline Inhibitor" J. Biol. Chem. 2774(8):46265-46727 (2002). 152. Traxler et al. "Protein tyrosine kinase inhibitors in cancer treatment (Part II)" Exp. Opin. Ther. Patents 7(6):571-588 (1997). 153. Travler et al. "Tyrosine kinase inhibitors in cancer treatment (Part II)" Exp. Opin. Ther. Patents 8(12):1599-1625 (1998). 154. Tsou et al. "G-Substituted-4-(3-bromophenylamino)quinazolines as Putative Irreversible Inhibitors of the Epidermal Growth Factor Receptor (HER-2) Tyrosine Kinases with Enhanced Antitumor Activity" J. Med. Chem. 44:2719-2734 (2001).  155. Vema et al. "Dissign of EGFR kinas										
143. WO 2005/026157 March 24, 2005 WIPO 144. WO 2005/030757 April 7, 2005 WIPO 145. WO 2005/030756 April 7, 2005 WIPO 146. WO 2005/0375439 August 18, 2005 WIPO 147. Gaul et al. "Discovery and Biological Evaluation of Potent Dual ErB-Z/EGFR tyrosine Kinase Inhibitors: Bioorganic & Medicinal Chemistry Letters 13: 637-640 (2003). 148. Hennequin et al. "Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase Inhibitors" Journal Of Medicinal Chemistry 42:5369-5389 (1999). 149. Hennequin et al. "Novel 4-amilinoquinazolines with C-7 basic side chains: Design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors" Journal Of Medicinal Chemistry 42:5369-5389 (1999). 149. Hennequin et al. "Novel 4-amilinoquinazolines with C-7 basic side chains: Design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors" Journal Of Medicinal Chemistry 43(7):1312 (2002). 150. Smail et al. "Tyrosine kinase Inhibitors. 17. Irreversible Inhibitors of the Epidermal Growth Factor Receptor: 4. (phenylamino)quinazoline- and 4-(phenylamino0pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizin function" Journal of Medicinal Chemistry 43(7):1380-1397 (2000). 151. Stamos et al. "Structure of the Epidermal Growth Factor Receptor Kinase Domain Alone and in Complex with a 4-Anilinoquinazoline Inhibitor" J. Biol. Chem. 277(48):46265-46272 (2002). 152. Traxler et al. "Tyrosine kinase inhibitors in cancer treatment" Exp. Opin. Ther. Patents 7(6):571-588 (1997). 153. Traxler et al. "Tyrosine kinase inhibitors in cancer treatment (Part II)" Exp. Opin. Ther. Patents 8(12):1599-1625 (1998).  154. Tsou et al. "Gesubstituted-4-(3-bromophenylamino)quinazolines as Putative Irreversible Inhibitors of the Epidermal Growth Factor Receptor (EGFR) and Human Epidermal Growth Factor Receptor (HER-2) Tyrosine Kinases with Enhanced Antitumor Activity" J. Med. Chem. 44:2719-2734 (2001).  155. Vern	<del></del>							$\Gamma$		
144. WO 2005/030767 April 7, 2005 WIPO 145. WO 2005/030765 April 7, 2005 WIPO 146. WO 2005/075439 August 18, 2005 WIPO  ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /T.N./ OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)  147. Gaul et al. "Discovery and Biological Evaluation of Potent Dual ErB-2/EGFR tyrosine Kinase Inhibitors-6- thiazolylquinazolines" Bioorganic & Medicinal Chemistry Letters 13: 637-640 (2003).  148. Hennequin et al. "Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors" Journal Of Medicinal Chemistry 42:5369-5389 (1999).  149. Hennequin et al. "Novel 4-anilinoquinazolines with C-7 basic side chains: Design and structure activity relationship o a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors" Journal Of Medicinal Chemistry 45:(6):1306 1312 (2002).  150. Smaill et al. "Tyrosine kinase Inhibitors. 17. Irreversible Inhibitors of the Epidermal Growth Factor Receptor: 4- (phenylamino)quinazoline- and 4-(phenylaminoOpyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizin function" Journal of Medicinal Chemistry 43(7):1380-1397 (2000).  151. Stamos et al. "Structure of the Epidermal Growth Factor Receptor Kinase Domain Alone and in Complex with a 4- Anilinoquinazoline Inhibitor" J. Biol. Chem. 277(48):46266-46272 (2002).  152. Trakler et al. "Protein tyrosine kinase inhibitors in cancer treatment (Part II)" Exp. Opin. Ther. Patents 7(6):571-588 (1997).  153. Trakler et al. "Protein tyrosine kinase inhibitors in cancer treatment (Part II)" Exp. Opin. Ther. Patents 7(6):571-588 (1997).  154. Tsou et al. "6-Substituted-4-(3-bromophenylamino)quinazolines as Putative Irreversible Inhibitors of the Epidermal Growth Factor Receptor (EGFR) and Human Epidermal Growth Factor Receptor (HER-2) Tyrosine Kinases with Enhanced Antitumor Activity" J. Med. Chem. 44:2719-2734 (2001).  155. Verna et al. "Design of EGFR kinase inhibitors in cancer treatment (Part II)" Exp. Opin. Ther. Patents 8	<del></del>						<b></b>	<del>                                     </del>		
145. WO 2005/030765 April 7, 2005 WIPO  146. WO 2005/075439 August 18, 2005 WIPO  ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /T.N./ OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)  147. Gaul et al. "Discovery and Biological Evaluation of Potent Dual ErB-2/EGFR tyrosine Kinase Inhibitors:6-thiazolylquinazolines" Bioorganic & Medicinal Chemistry Letters 13: 637-640 (2003).  148. Hennequin et al. "Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors" Journal Of Medicinal Chemistry 42:5369-5389 (1999).  149. Hennequin et al. "Novel 4-amilinoquinazolines with C-7 basic side chains: Design and structure activity relationship o a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors" Journal Of Medicinal Chemistry 45(6):1306 (2002).  150. Smaill et al. "Tyrosine kinase Inhibitors. 17. Irreversible Inhibitors of the Epidermal Growth Factor Receptor: 4-(phenylamino)quinazoline- and 4-(phenylaminolopyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizin, function" Journal of Medicinal Chemistry 43(7):1380-1397 (2000).  151. Stamos et al. "Structure of the Epidermal Growth Factor Receptor Kinase Domain Alone and in Complex with a 4-Anilinoquinazoline Inhibitor" J. Biol. Chem. 277(48):46265-46272 (2002).  152. Traxler et al. "Tyrosine kinase inhibitors in cancer treatment" Exp. Opin. Ther. Patents 7(6):571-588 (1997).  153. Traxler et al. "Tyrosine kinase inhibitors in cancer treatment (Part II)" Exp. Opin. Ther. Patents 8(12):1599-1625 (1998).  154. Tsou et al. "6-Substituted-4-(3-bromophenylamino)quinazolines as Putative Irreversible Inhibitors of the Epidermal Growth Factor Receptor (EGFR) and Human Epidermal Growth Factor Receptor (HER-2) Tyrosine Kinases with Enhanced Antitumor Activity" J. Med. Chem. 44:2719-2734 (2001).  155. Verna et al. "Design of EGFR kinase inhibitors in gland-based approach and its confirmation with structure-based studies" Bioorg Med Chem. 11(21):4643-4653 (2003) .	<del></del>				<del>'—</del>		<del> </del>	<del></del>	<u> </u>	
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /T.N./ OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)  147. Gaul et al. "Discovery and Biological Evaluation of Potent Dual ErB-2/EGFR tyrosine Kinase Inhibitors:6- thiazolylquinazolines" Bioorganic & Medicinal Chemistry Letters 13: 637-640 (2003).  148. Hennequin et al. "Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors" Journal Of Medicinal Chemistry 42:5369-5389 (1999).  149. Hennequin et al. "Novel 4-anilinoquinazolines with C-7 basic side chains: Design and structure activity relationship o a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors" Journal Of Medicinal Chemistry 45(6):1300 1312 (2002).  150. Smaill et al. "Tyrosine kinase Inhibitors. 17. Irreversible Inhibitors of the Epidermal Growth Factor Receptor: 4- (phenylamino)quinazoline- and 4-(phenylaminoOpyritol)gryrimidine-6-acrylamides bearing additional solubilizin function" Journal of Medicinal Chemistry 43(7):1380-1397 (2000).  151. Stamos et al. "Structure of the Epidermal Growth Factor Receptor Kinase Domain Alone and in Complex with a 4- Anilinoquinazoline Inhibitor" J. Biol. Chem. 277(48):46265-46272 (2002).  152. Traxler et al. "Tyrosine kinase inhibitors in cancer treatment (Part II)" Exp. Opin. Ther. Patents 7(6):571-588 (1997).  153. Traxler et al. "Tyrosine kinase inhibitors in cancer treatment (Part II)" Exp. Opin. Ther. Patents 8(12):1599-1625 (1998).  154. Tsou et al. "6-Substituted-4-(3-bromophenylamino)quinazolines as Putative Irreversible Inhibitors of the Epidermal Growth Factor Receptor (EGFR) and Human Epidermal Growth Factor Receptor (HER-2) Tyrosine Kinases with Enhanced Antitumor Activity" J. Med. Chem. 44:2719-2734 (2001).  155. Verma et al. "Design of EGFR kinase inhibitors: a ligand-based approach and its confirmation with structure-based studies" Bioorg Med Chem. 11(21):4643-4653 (2003) .						<del></del>	<del> </del>	<del>                                     </del>	<del></del>	
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. 7T.N./ OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)  147. Gaul et al. "Discovery and Biological Evaluation of Potent Dual ErB-2/EGFR tyrosine Kinase Inhibitors:6-thiazolylquinazolines" Bioorganic & Medicinal Chemistry Letters 13: 637-640 (2003).  148. Hennequin et al. "Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors" Journal Of Medicinal Chemistry 42:5369-5389 (1999).  149. Hennequin et al. "Novel 4-anilinoquinazolines with C-7 basic side chains: Design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors" Journal Of Medicinal Chemistry 45(6):130(1312 (2002).  150. Smaill et al. "Tyrosine kinase Inhibitors. 17. Irreversible Inhibitors of the Epidermal Growth Factor Receptor: 4- (phenylamino)quinazoline- and 4-(phenylamino0pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizin function" Journal of Medicinal Chemistry 43(7):1380-1397 (2000).  151. Stamos et al. "Structure of the Epidermal Growth Factor Receptor Kinase Domain Alone and in Complex with a 4- Anilinoquinazoline Inhibitor" J. Biol. Chem. 277(48):46265-46272 (2002).  152. Traxler et al. "Protein tyrosine kinase inhibitors in cancer treatment" Exp. Opin. Ther. Patents 7(6):571-588 (1997).  153. Traxler et al. "Tyrosine kinase inhibitors in cancer treatment (Part II)" Exp. Opin. Ther. Patents 8(12):1599-1625 (1998).  154. Tsou et al. "6-Substituted-4-(3-bromophenylamino)quinazolines as Putative Irreversible Inhibitors of the Epidermal Growth Factor Receptor (EGFR) and Human Epidermal Growth Factor Receptor (HER-2) Tyrosine Kinases with Enhanced Antitumor Activity" J. Med. Chem. 44:2719-2734 (2001).  155. Vema et al. "Design of EGFR kinase inhibitors: a ligand-based approach and its confirmation with structure-based studies" Bioorg Med Chem. 11(21):4643-4653 (2003) .							<del></del>	<del>  </del>	<del> </del>	
147. Gaul et al. "Discovery and Biological Evaluation of Potent Dual ErB-2/EGFR tyrosine Kinase Inhibitors:6-thiazolylquinazolines" Bioorganic & Medicinal Chemistry Letters 13: 637-640 (2003).  148. Hennequin et al. "Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors" Journal Of Medicinal Chemistry 42:5369-5389 (1999).  149. Hennequin et al. "Novel 4-amilinoquinazolines with C-7 basic side chains: Design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors" Journal Of Medicinal Chemistry 45(6):1300 (1312 (2002).  150. Smaill et al. "Tyrosine kinase Inhibitors. 17. Irreversible Inhibitors of the Epidermal Growth Factor Receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing function" Journal of Medicinal Chemistry 43(7):1380-1397 (2000).  151. Stamos et al. "Structure of the Epidermal Growth Factor Receptor Kinase Domain Alone and in Complex with a 4-Anilinoquinazoline Inhibitor" J. Biol. Chem. 277(48):46265-46272 (2002).  152. Traxler et al. "Protein tyrosine kinase inhibitors in cancer treatment" Exp. Opin. Ther. Patents 7(6):571-588 (1997), 153. Traxler et al. "Tyrosine kinase inhibitors in cancer treatment (Part II)" Exp. Opin. Ther. Patents 8(12):1599-1625 (1998).  154. Tsou et al. "G-Substituted-4-(3-bromophenylamino)quinazolines as Putative Irreversible Inhibitors of the Epidermal Growth Factor Receptor (EGFR) and Human Epidermal Growth Factor Receptor (HER-2) Tyrosine Kinases with Enhanced Antitumor Activity" J. Med. Chem. 44:719-2734 (2001).  155. Verna et al. "Design of EGFR kinase inhibitors: a ligand-based approach and its confirmation with structure-based studies" Bioorg Med Chem. 11(21):4643-4653 (2003).		170.	WU ZUUJU JUJU	August 10, 2002	<del>'</del>	WIFO	<del></del>	+	<del></del>	
147. Gaul et al. "Discovery and Biological Evaluation of Potent Dual ErB-2/EGFR tyrosine Kinase Inhibitors:6-thiazolylquinazolines" Bioorganic & Medicinal Chemistry Letters 13: 637-640 (2003).  148. Hennequin et al. "Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors" Journal Of Medicinal Chemistry 42:5369-5389 (1999).  149. Hennequin et al. "Novel 4-amilinoquinazolines with C-7 basic side chains: Design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors" Journal Of Medicinal Chemistry 45(6):1300 (1312 (2002).  150. Smaill et al. "Tyrosine kinase Inhibitors. 17. Irreversible Inhibitors of the Epidermal Growth Factor Receptor: 4-(phenylamino)quinazoline- and 4-(phenylaminoppyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing function." Journal of Medicinal Chemistry 43(7):1380-1397 (2000).  151. Stamos et al. "Structure of the Epidermal Growth Factor Receptor Kinase Domain Alone and in Complex with a 4-Anilinoquinazoline Inhibitor." J. Biol. Chem. 277(48):46265-46272 (2002).  152. Traxler et al. "Protein tyrosine kinase inhibitors in cancer treatment" Exp. Opin. Ther. Patents 7(6):571-588 (1997), 153. Traxler et al. "Tyrosine kinase inhibitors in cancer treatment" Exp. Opin. Ther. Patents 8(12):1599-1625 (1998).  154. Tsou et al. "G-Substituted-4-(3-bromophenylamino)quinazolines as Putative Irreversible Inhibitors of the Epidermal Growth Factor Receptor (EGFR) and Human Epidermal Growth Factor Receptor (HER-2) Tyrosine Kinases with Enhanced Antitumor Activity" J. Med. Chem. 44:2719-2734 (2001).  155. Vema et al. "Design of EGFR kinase inhibitors: a ligand-based approach and its confirmation with structure-based studies" Bioorg Med Chem. 11(21):4643-4653 (2003) .		ALL	REFERENCES CO	NSIDERED EXCE	γTα	WHERE LINED THRO	и <del>ligh. /Т</del>	<sup>1</sup> N./		
147. Gaul et al. "Discovery and Biological Evaluation of Potent Dual ErB-2/EGFR tyrosine Kinase Inhibitors:6-thiazolylquinazolines" Bioorganic & Medicinal Chemistry Letters 13: 637-640 (2003).  148. Hennequin et al. "Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors" Journal Of Medicinal Chemistry 42:5369-5389 (1999).  149. Hennequin et al. "Novel 4-anilinoquinazolines with C-7 basic side chains: Design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors" Journal Of Medicinal Chemistry 45(6):130(1312 (2002).  150. Smaill et al. "Tyrosine kinase Inhibitors. 17. Irreversible Inhibitors of the Epidermal Growth Factor Receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino0pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing function" Journal of Medicinal Chemistry 43(7):1380-1397 (2000).  151. Stamos et al. "Structure of the Epidermal Growth Factor Receptor Kinase Domain Alone and in Complex with a 4-Anilinoquinazoline Inhibitor" J. Biol. Chem. 277(48):46265-46272 (2002).  152. Traxler et al. "Protein tyrosine kinase inhibitors in cancer treatment" Exp. Opin. Ther. Patents 7(6):571-588 (1997).  153. Traxler et al. "Tyrosine kinase inhibitors in cancer treatment (Part II)" Exp. Opin. Ther. Patents 8(12):1599-1625 (1998).  154. Tsou et al. "6-Substituted-4-(3-bromophenylamino)quinazolines as Putative Irreversible Inhibitors of the Epidermal Growth Factor Receptor (EGFR) and Human Epidermal Growth Factor Receptor (HER-2) Tyrosine Kinases with Enhanced Antitumor Activity" J. Med. Chem. 44:2719-2734 (2001).  155. Verma et al. "Design of EGFR kinase inhibitors: a ligand-based approach and its confirmation with structure-based studies" Bioorg Med Chem. 11(21):4643-4653 (2003).			OTHER DO	OCUMENTS (Includ	ding A	Author, Title, Date, Pert	tinent Pag	ges. etc.)		
thiazolylquinazolines' Bioorganic & Medicinal Chemistry Letters 13: 637-640 (2003).  148. Hennequin et al. "Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors" Journal Of Medicinal Chemistry 42:5369-5389 (1999).  149. Hennequin et al. "Novel 4-anilinoquinazolines with C-7 basic side chains: Design and structure activity relationship o a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors" Journal Of Medicinal Chemistry 45(6):1300 (1312 (2002).  150. Smaill et al. "Tyrosine kinase Inhibitors. 17. Irreversible Inhibitors of the Epidermal Growth Factor Receptor: 4- (phenylamino)quinazoline- and 4-(phenylamino0pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing function" Journal of Medicinal Chemistry 43(7):1380-1397 (2000).  151. Stamos et al. "Structure of the Epidermal Growth Factor Receptor Kinase Domain Alone and in Complex with a 4- Anilinoquinazoline Inhibitor" J. Biol. Chem. 277(48):46265-46272 (2002).  152. Traxler et al. "Protein tyrosine kinase inhibitors in cancer treatment" Exp. Opin. Ther. Patents 7(6):571-588 (1997).  153. Traxler et al. "Tyrosine kinase inhibitors in cancer treatment" Exp. Opin. Ther. Patents 8(12):1599-1625 (1998).  154. Tsou et al. "6-Substituted-4-(3-bromophenylamino)quinazolines as Putative Irreversible Inhibitors of the Epidermal Growth Factor Receptor (EGFR) and Human Epidermal Growth Factor Receptor (HER-2) Tyrosine Kinases with Enhanced Antitumor Activity" J. Med. Chem. 44:2719-2734 (2001).  155. Verma et al. "Design of EGFR kinase inhibitors: a ligand-based approach and its confirmation with structure-based studies" Bioorg Med Chem. 11(21):4643-4653 (2003).		147.	Gaul et al. "Discovery	y and Biological Evalu	uation	of Potent Dual ErB-2/EC	GFR tyrosi	sine Kinase lr	nhibitors:6-	
148. Hennequin et al. "Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors" Journal Of Medicinal Chemistry 42:5369-5389 (1999).  149. Hennequin et al. "Novel 4-anilinoquinazolines with C-7 basic side chains: Design and structure activity relationship o a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors" Journal Of Medicinal Chemistry 45(6):1300 (1312 (2002).  150. Smaill et al. "Tyrosine kinase Inhibitors. 17. Irreversible Inhibitors of the Epidermal Growth Factor Receptor: 4- (phenylamino)quinazoline- and 4-(phenylaminopyrido]3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing function" Journal of Medicinal Chemistry 43(7):1380-1397 (2000).  151. Stamos et al. "Structure of the Epidermal Growth Factor Receptor Kinase Domain Alone and in Complex with a 4- Anilinoquinazoline Inhibitor" J. Biol. Chem. 277(48):46265-46272 (2002).  152. Traxler et al. "Protein tyrosine kinase inhibitors in cancer treatment" Exp. Opin. Ther. Patents 7(6):571-588 (1997).  153. Traxler et al. "Tyrosine kinase inhibitors in cancer treatment (Part II)" Exp. Opin. Ther. Patents 8(12):1599-1625 (1998).  154. Tsou et al. "6-Substituted-4-(3-bromophenylamino)quinazolines as Putative Irreversible Inhibitors of the Epidermal Growth Factor Receptor (EGFR) and Human Epidermal Growth Factor Receptor (HER-2) Tyrosine Kinases with Enhanced Antitumor Activity" J. Med. Chem. 44:2719-2734 (2001).  155. Verna et al. "Design of EGFR kinase inhibitors: a ligand-based approach and its confirmation with structure-based studies" Bioorg Med Chem. 11(21):4643-4653 (2003)  Date Considered  O5/26/2009  Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609: draw line through citation if not in		_	thiazolylquinazolines"	"Bioorganic & Medic	cinal (	Chemistry Letters 13: 637	7-640 (200	03).		
inhibitors" Journal Of Medicinal Chemistry 42:5369-5389 (1999).  Hennequin et al. "Novel 4-amilinoquinazolines with C-7 basic side chains: Design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors" Journal Of Medicinal Chemistry 45(6):1300 (1312 (2002).  150. Smaill et al. "Tyrosine kinase Inhibitors. 17. Irreversible Inhibitors of the Epidermal Growth Factor Receptor: 4- (phenylamino)quinazoline- and 4-(phenylamino)qpyrindo[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing function" Journal of Medicinal Chemistry 43(7):1380-1397 (2000).  151. Stamos et al. "Structure of the Epidermal Growth Factor Receptor Kinase Domain Alone and in Complex with a 4- Anilinoquinazoline Inhibitor" J. Biol. Chem. 277(48):46265-46272 (2002).  152. Traxler et al. "Protein tyrosine kinase inhibitors in cancer treatment" Exp. Opin. Ther. Patents 7(6):571-588 (1997).  153. Traxler et al. "Tyrosine kinase inhibitors in cancer treatment (Part II)" Exp. Opin. Ther. Patents 8(12):1599-1625 (1998).  154. Tsou et al. "G-Substituted-4-(3-bromophenylamino)quinazolines as Putative Irreversible Inhibitors of the Epidermal Growth Factor Receptor (EGFR) and Human Epidermal Growth Factor Receptor (HER-2) Tyrosine Kinases with Enhanced Antitumor Activity" J. Med. Chem. 44:2719-2734 (2001).  155. Verna et al. "Design of EGFR kinase inhibitors: a ligand-based approach and its confirmation with structure-based studies" Bioorg Med Chem. 11(21):4643-4653 (2003).		148.	Hennequin et al. "Desi	sign and structure-activ	ivity re	elationship of a new class	s of potent	VEGF rece	ptor tyrosine kinase	
a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors" Journal Of Medicinal Chemistry 45(6):1300 (1312 (2002).  150. Smaill et al. "Tyrosine kinase Inhibitors. 17. Irreversible Inhibitors of the Epidermal Growth Factor Receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino0pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing function" Journal of Medicinal Chemistry 43(7):1380-1397 (2000).  151. Stamos et al. "Structure of the Epidermal Growth Factor Receptor Kinase Domain Alone and in Complex with a 4-Anilinoquinazoline Inhibitor" J. Biol. Chem. 277(48):46265-46272 (2002).  152. Traxler et al. "Protein tyrosine kinase inhibitors in cancer treatment" Exp. Opin. Ther. Patents 7(6):571-588 (1997).  153. Traxler et al. "Tyrosine kinase inhibitors in cancer treatment (Part II)" Exp. Opin. Ther. Patents 8(12):1599-1625 (1998).  154. Tsou et al. "6-Substituted-4-(3-bromophenylamino)quinazolines as Putative Irreversible Inhibitors of the Epidermal Growth Factor Receptor (EGFR) and Human Epidermal Growth Factor Receptor (HER-2) Tyrosine Kinases with Enhanced Antitumor Activity" J. Med. Chem. 44:2719-2734 (2001).  155. Verna et al. "Design of EGFR kinase inhibitors: a ligand-based approach and its confirmation with structure-based studies" Bioorg Med Chem. 11(21):4643-4653 (2003) .  (Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609: draw line through citation if not in	<u>'</u>		inhibitors" Journal Of I	Medicinal Chemistry	y 42:53	369-5389 (1999) .		_		
1312 (2002).  150. Smaill et al. "Tyrosine kinase Inhibitors. 17. Irreversible Inhibitors of the Epidermal Growth Factor Receptor: 4-(phenylamino)quinazoline- and 4-(phenylaminoOpyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing function" Journal of Medicinal Chemistry 43(7):1380-1397 (2000).  151. Stamos et al. "Structure of the Epidermal Growth Factor Receptor Kinase Domain Alone and in Complex with a 4-Anilinoquinazoline Inhibitor" J. Biol. Chem. 277(48):46265-46272 (2002).  152. Traxler et al. "Protein tyrosine kinase inhibitors in cancer treatment" Exp. Opin. Ther. Patents 7(6):571-588 (1997).  153. Traxler et al. "Tyrosine kinase inhibitors in cancer treatment (Part II)" Exp. Opin. Ther. Patents 8(12):1599-1625 (1998).  154. Tsou et al. "6-Substituted-4-(3-bromophenylamino)quinazolines as Putative Irreversible Inhibitors of the Epidermal Growth Factor Receptor (EGFR) and Human Epidermal Growth Factor Receptor (HER-2) Tyrosine Kinases with Enhanced Antitumor Activity" J. Med. Chem. 44:2719-2734 (2001).  155. Verna et al. "Design of EGFR kinase inhibitors: a ligand-based approach and its confirmation with structure-based studies" Bioorg Med Chem. 11(21):4643-4653 (2003) .  (xaminer: Initial if reference considered, whether or not citation is in conformance with MPEP 609 draw line through citation if not in	,	149.	Hennequin et al. "Nove	el 4-anilinoquinazolir	nes w	ith C-7 basic side chains	: Design 2	and structure	activity relationship of	
150. Smaill et al. "Tyrosine kinase Inhibitors. 17. Irreversible Inhibitors of the Epidermal Growth Factor Receptor: 4- (phenylamino)quinazoline- and 4-(phenylamino0pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing function" Journal of Medicinal Chemistry 43(7):1380-1397 (2000).   151. Stamos et al. "Structure of the Epidermal Growth Factor Receptor Kinase Domain Alone and in Complex with a 4- Anilinoquinazoline Inhibitor" J. Biol. Chem. 277(48):46265-46272 (2002).   152. Traxler et al. "Protein tyrosine kinase inhibitors in cancer treatment" Exp. Opin. Ther. Patents 7(6):571-588 (1997).   153. Traxler et al. "Tyrosine kinase inhibitors in cancer treatment (Part II)" Exp. Opin. Ther. Patents 8(12):1599-1625 (1998).   154. Tsou et al. "6-Substituted-4-(3-bromophenylamino)quinazolines as Putative Irreversible Inhibitors of the Epidermal Growth Factor Receptor (EGFR) and Human Epidermal Growth Factor Receptor (HER-2) Tyrosine Kinases with Enhanced Antitumor Activity" J. Med. Chem. 44:2719-2734 (2001).   155. Vema et al. "Design of EGFR kinase inhibitors: a ligand-based approach and its confirmation with structure-based studies" Bioorg Med Chem. 11(21):4643-4653 (2003) -   156. Staminer: Initial if reference considered, whether or not citation is in conformance with MPEP 609: draw line through citation if not in	,	r	a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors" Journal Of Medicinal Chemistry 45(6):1300							
[phenylamino)quinazoline- and 4-(phenylamino0pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing function" Journal of Medicinal Chemistry 43(7):1380-1397 (2000).  151. Stamos et al. "Structure of the Epidermal Growth Factor Receptor Kinase Domain Alone and in Complex with a 4-Anilinoquinazoline Inhibitor" J. Biol. Chem. 277(48):46265-46272 (2002).  152. Traxler et al. "Protein tyrosine kinase inhibitors in cancer treatment" Exp. Opin. Ther. Patents 7(6):571-588 (1997).  153. Traxler et al. "Tyrosine kinase inhibitors in cancer treatment (Part II)" Exp. Opin. Ther. Patents 8(12):1599-1625 (1998).  154. Tsou et al. "6-Substituted-4-(3-bromophenylamino)quinazolines as Putative Irreversible Inhibitors of the Epidermal Growth Factor Receptor (EGFR) and Human Epidermal Growth Factor Receptor (HER-2) Tyrosine Kinases with Enhanced Antitumor Activity" J. Med. Chem. 44:2719-2734 (2001).  155. Vema et al. "Design of EGFR kinase inhibitors: a ligand-based approach and its confirmation with structure-based studies" Bioorg Med Chem. 11(21):4643-4653 (2003) .  Date Considered 05/26/2009  Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609: draw line through citation if not in				The Indiana 17	- T	" t T 1.11 is an of the	- 11	- 1 p.		
function" Journal of Medicinal Chemistry 43(7):1380-1397 (2000).  151. Stamos et al. "Structure of the Epidermal Growth Factor Receptor Kinase Domain Alone and in Complex with a 4-Anilinoquinazoline Inhibitor" J. Biol. Chem. 277(48):46265-46272 (2002).  152. Traxler et al. "Protein tyrosine kinase inhibitors in cancer treatment" Exp. Opin. Ther. Patents 7(6):571-588 (1997).  153. Traxler et al. "Tyrosine kinase inhibitors in cancer treatment (Part II)" Exp. Opin. Ther. Patents 8(12):1599-1625 (1998).  154. Tsou et al. "6-Substituted-4-(3-bromophenylamino)quinazolines as Putative Irreversible Inhibitors of the Epidermal Growth Factor Receptor (EGFR) and Human Epidermal Growth Factor Receptor (HER-2) Tyrosine Kinases with Enhanced Antitumor Activity" J. Med. Chem. 44:2719-2734 (2001).  155. Vema et al. "Design of EGFR kinase inhibitors: a ligand-based approach and its confirmation with structure-based studies" Bioorg Med Chem. 11(21):4643-4653 (2003).  Date Considered 05/26/2009  Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609: draw line through citation if not in	1	130.	Smalli et al. 1 yrosino	/ kinase innibitors. 17.	. Inc	versible inhibitors of the	Epiderma	Growth rac	tor Receptor: 4-	
151. Stamos et al. "Structure of the Epidermal Growth Factor Receptor Kinase Domain Alone and in Complex with a 4-Anilinoquinazoline Inhibitor" J. Biol. Chem. 277(48):46265-46272 (2002).  152. Traxler et al. "Protein tyrosine kinase inhibitors in cancer treatment" Exp. Opin. Ther. Patents 7(6):571-588 (1997).  153. Traxler et al. "Tyrosine kinase inhibitors in cancer treatment (Part II)" Exp. Opin. Ther. Patents 8(12):1599-1625 (1998).  154. Tsou et al. "6-Substituted-4-(3-bromophenylamino)quinazolines as Putative Irreversible Inhibitors of the Epidermal Growth Factor Receptor (EGFR) and Human Epidermal Growth Factor Receptor (HER-2) Tyrosine Kinases with Enhanced Antitumor Activity" J. Med. Chem. 44:2719-2734 (2001).  155. Verna et al. "Design of EGFR kinase inhibitors: a ligand-based approach and its confirmation with structure-based studies" Bioorg Med Chem. 11(21):4643-4653 (2003).  Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609: draw line through citation if not in	,	1 1	function" Journal of M	Inc- and 4-(phonym	Miloo,	pyrido[3,2-a]pyriiiiiuiii-	-6-асгуган	nides bearing	g additional solubilizing	
Anilinoquinazoline Inhibitor" J. Biol. Chem. 277(48):46265-46272 (2002).  152. Traxler et al. "Protein tyrosine kinase inhibitors in cancer treatment" Exp. Opin. Ther. Patents 7(6):571-588 (1997).  153. Traxler et al. "Tyrosine kinase inhibitors in cancer treatment (Part II)" Exp. Opin. Ther. Patents 8(12):1599-1625 (1998).  154. Tsou et al. "6-Substituted-4-(3-bromophenylamino)quinazolines as Putative Irreversible Inhibitors of the Epidermal Growth Factor Receptor (EGFR) and Human Epidermal Growth Factor Receptor (HER-2) Tyrosine Kinases with Enhanced Antitumor Activity" J. Med. Chem. 44:2719-2734 (2001).  155. Vema et al. "Design of EGFR kinase inhibitors: a ligand-based approach and its confirmation with structure-based studies" Bioorg Med Chem. 11(21):4643-4653 (2003).  Cxaminer: Initial if reference considered, whether or not citation is in conformance with MPEP 609: draw line through citation if not in		151.	Stamos et al. "Structur	re of the Epidermal G	owth	Factor Receptor Kinase	Domain /	A lone and in	Complex with a 4.	
152. Traxler et al. "Protein tyrosine kinase inhibitors in cancer treatment" Exp. Opin. Ther. Patents 7(6):571-588 (1997).  153. Traxler et al. "Tyrosine kinase inhibitors in cancer treatment (Part II)" Exp. Opin. Ther. Patents 8(12):1599-1625 (1998).  154. Tsou et al. "6-Substituted-4-(3-bromophenylamino)quinazolines as Putative Irreversible Inhibitors of the Epidermal Growth Factor Receptor (EGFR) and Human Epidermal Growth Factor Receptor (HER-2) Tyrosine Kinases with Enhanced Antitumor Activity" J. Med. Chem. 44:2719-2734 (2001).  155. Vema et al. "Design of EGFR kinase inhibitors: a ligand-based approach and its confirmation with structure-based studies" Bioorg Med Chem. 11(21):4643-4653 (2003).  Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609: draw line through citation if not in	!		Anilinoquinazoline Inh	hibitor" J. Biol. Chem	n. 277(	7(48):46265-46272 (2002)	:) _		•	
153. Traxler et al. "Tyrosine kinase inhibitors in cancer treatment (Part II)" Exp. Opin. Ther. Patents 8(12):1599-1625 (1998).  154. Tsou et al. "6-Substituted-4-(3-bromophenylamino)quinazolines as Putative Irreversible Inhibitors of the Epidermal Growth Factor Receptor (EGFR) and Human Epidermal Growth Factor Receptor (HER-2) Tyrosine Kinases with Enhanced Antitumor Activity" J. Med. Chem. 44:2719-2734 (2001).  155. Vema et al. "Design of EGFR kinase inhibitors: a ligand-based approach and its confirmation with structure-based studies" Bioorg Med Chem. 11(21):4643-4653 (2003).  Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609: draw line through citation if not in		<u>  152.</u> [	Traxler et al. "Protein t	tyrosine kinase inhibit	itors ir	in cancer treatment" Exp.	Opin. The	er. Patents 7(	(6):571-588 (1997).	
Growth Factor Receptor (EGFR) and Human Epidermal Growth Factor Receptor (HER-2) Tyrosine Kinases with Enhanced Antitumor Activity" J. Med. Chem. 44:2719-2734 (2001).  155. Vema et al. "Design of EGFR kinase inhibitors: a ligand-based approach and its confirmation with structure-based studies" Bioorg Med Chem. 11(21):4643-4653 (2003).  Examiner    Tamthom Truong   Date Considered   05/26/2009		153.	Traxler et al. "Tyrosine (1998)	e kinase inhibitors in o	cance	er treatment (Part II)" Exp	p. Opin. Ti	her. Patents 8	8(12):1599-1625	
Growth Factor Receptor (EGFR) and Human Epidermal Growth Factor Receptor (HER-2) Tyrosine Kinases with Enhanced Antitumor Activity" J. Med. Chem. 44:2719-2734 (2001).  155. Vema et al. "Design of EGFR kinase inhibitors: a ligand-based approach and its confirmation with structure-based studies" Bioorg Med Chem. 11(21):4643-4653 (2003).  Examiner    Tamthom Truong   Date Considered   05/26/2009	,	154.	Tsou et al. "6-Substitut	ted-4-(3-bromopheny)	lamin	io)quinazolines as Putativ	/e Irrevers	ible Inhibito	ors of the Epidermal	
155. Vema et al. "Design of EGFR kinase inhibitors: a ligand-based approach and its confirmation with structure-based studies" Bioorg Med Chem. 11(21):4643-4653 (2003) •  Examiner    Tamthom Truong   Date Considered   05/26/2009	1	1 K	Growth Factor Recepto	or (EGFR) and Humar	an Epic	idermal Growth Factor Re	ceptor (H	(ER-2) Tyros	sine Kinases with	
Studies" Bioorg Med Chem. 11(21):4643-4653 (2003) •  Examiner    Tamthom Truong   Date Considered   05/26/2009    Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609: draw line through citation if not in	<del></del>	155	himanced Antitumor A	ctivity" J. Med. Chen	m. 44.	:2719-2734 (2001) .	1 :42 001		14	
Examiner /Tamthom Truong/ Date Considered 05/26/2009  Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609: draw line through citation if not in		155.	studies" Bioorg Med C	Chem. 11(21):4643-46	ب .ors 2 <u>) 553</u>	ligano-based approach a (003) •	nd its com	firmation wi	th structure-based	
/Tamthom Truong/ 05/26/2009 Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609: draw line through citation if not in		<del></del>								
/Tamthom Truong/ 05/26/2009 Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609: draw line through citation if not in								<del></del>		
/ I amthom I ruong/ U5/26/2009  Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609: draw line through citation if not in	Examiner		T- with an Truc	Date Co	onsid	ered OF 1961'	2000			
Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in		2 141_1		ong/		05/26/2		<u></u> -	· —	
	xaminer:	Initial	if reference considered	I, whether or not citati	ion is	in conformance with MP	'EP 609; c	draw line thre	ough citation if not in	

# INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Applicants: HENNEQUIN et

Attorney Docket No. 056291-5241

Application No. 10/573,090

SEP 0 7 2006

Correction of PTO Form 1449 Filed September 1, 2006

Filing Date: March 15, 2006

5, 2006 Art Unit: Unassigned

			U.S. PATEN	T DOCUMENTS			
Initial		Document No.	Date	Name	Class	Sub-Class	Filing Date
	1.	US 20020049197	April 25, 2002	Himmelsbach et al.	514	217.06	August 23, 2001
	2.	US 20020082270	June 27, 2002	Himmelsbach et al.	514	266/2	August 22, 2001
	3.	US 20020082271	June 27, 2002	Himmelsbach et al.	514	266.24	August 22, 2001
	4.	US 20020128353	September 12, 2002	Mishani et al.	600	431	March 12, 2001
	5.	US 20020169188	November 14, 2002	Himmelsbach et al.	514	266.4	December 10, 2001
	6.	US 20020173509	November 21, 2002	Himmelsbach et al.	514	234.5	December 17, 2001
	7.	US 20020177601	November 28, 2002	Himmelsbach et al.	514	266.2	August 23, 2001
	8.	US 20030149062	August 7, 2003	Jung et al.	614	266.22	January 29, 2003
	9.	US 20030158196	August 21, 2003	Jung et al.	514	234.2	February 7, 2003
	10.	US 20030225079	December 4, 2003	Singer et al.	514	233.8	May 8, 2003
	11.	US 20040044014	March 4, 2004	Himmelsbach et al	514	266.4	April 17, 2003
	12.	US 20040048880	March N, 2004	Himmelsbach et al.	514	266.2	March 27, 2003
	13.	US 20040176361	September 2 2004	Fujio et al.	514	224.2	February 24, 2004
	14.	US 20050148607	July 7, 2005	Suzuki et al.	514	264.11	June 3, 2003
	15.	US 20050165035	July 28, 2005	Bradbury et al.	514	266.22	June 1, 2004
	16.	US 3,812,257	May 21, 1974	Yamamoto	514	266.21	April 7, 1972
	17.	US 3,971,783	July 27, 1976	Barnish et al.	514	284	April 26, 1974
	18.	US 4,335,127	June 15, 1982	Vandenberk et al.	514	266.22	October 12, 1979
	19.	US 4,921,863	May 1, 1990	Sugimoto et al.	514	319	February 17, 1988
	20.	US 5,411,963	May 2, 1995	Dreikorn et al.	514	266.3	July 19, 1993
	21.	US 5,457,105	October 10, 1995	Barker	514	234.5	August 2, 1994
	22.	US 5,616,582	April 1, 1997	Rarker	514	234.5	June 15, 1995
	23.	US 5,747,498	May 5, 1998	Schnor et al.	514	266.4	May 28, 1996
	24.	US 5,770,599	June 23, 1988	Gibson	514	228.2	April 26, 1996
	25.	US 5,817,678	October 6/1998	Kim et al	514	326	November 15, 1996
	26.	US 6,127,366	October 3, 2000	Kim et al.	514	235.5	October 5, 1998
	27.	US 6,177,433	January 23, 2001	Uckun et al.	514	266.4	November 19, 1999
	28.	US 6,200,976	March 13, 2001	Ries et al.	514	249	March 29, 1999
	29.	US 6,297,258	october 2, 2001	Wissner et al.	514	313	August 1, 2000
	<del>30.</del>	<del>US 6,313,127</del>	November 6, 2001	Waterson et al.	514	<del>253.01</del>	<del>July 31, 1998</del>
	31.	<del>US-6,541,491</del>	April 1, 2003	Davies et al.	<del>5</del> 34	340	November 30, 2000
	32.	US 6,562,319	May 13, 2003	Mishani et al.	424	1.81	March 12, 2001
	33.	US 6,617,329	September 9, 2003	Himmelsbach et al.	514	252.14	August 23, 2001
	34.	US 6,653,305	November 25, 2003	Himmelsbach et al.	514	233.5	August 15, 2001

FOREIGN PATENT DOCUMENTS

Dogument No. Date Country Class Sub-Class Translation

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation in conformance and not considered. Include copy of this form with next communication to applicant.

## Application No. TPE Attorney Docket No. INFORMATION DISCLOSURE CITATION 10/573,090 056291-5241 (Use several sheets if necessary) SEP 0 7 2006 pplicants: HENNEQUIN et al. Correction of PTO Form 149 Group Art Unit: Unassigned Filing Date: March 15, 2006 iled September 1, 2006 **U.S. PATENT DOCUMENTS** Filing Date Class Sub-Class Name Initial Document No. Date August 22, 2001 514 266.4 Himmelsbach et al. December 2, 2003 35. US 6,656,946 August 22, 2001 228 514 Himmelsbach et al. US 6,740,651 May 25, 2004 36. 234.8 February 6, 2002 514 Himmelsbach et al. 37. US 6,972,288 December 6, 2005 FOREIGN PATENT DOCUMENTS Class Sub-Class Translation Country Date Document No. US 6,972,288 August 31, 2000 Germany 38. DE 19908567 May 11, 1994 **EPO** 39. EP 0 288 563 November 8, 1995 **EPO** 40. EP 0 566 226 **EPO** April 17, 2002 41. EP 0 585 371 August 30, 1995 **EPO** 42. EP 0 669 324 **EPO** April 22, 1998 EP 0 837 063 43. **EPQ** October 18, 2000 EP 1 044 969 44. EBÓ August 14, 2002 45. EP 1 230 919 **PO** 46. EP 1 369 418 December 10, 200 **EPO** June 29, 2005 47. EP 1 548 008 United Kingdom GB 2,295,387 May 29, 1996 48. US 4,921,863 WIPO 49. WO 88/02365 April 7, 1988 **WIPO** November 26, 1992 50. WO 92/20642 WO 95/00146 WIPO January 5, 1995 51. WIPO June 15, 1995 WO 95/15758 52. WIPO March 28, 1996 WO 96/09294 53. WIPO October 3, 1996 WO 96/30347 54. WIPO October 31/1996 55. WO 96/33977 October 71, 1996 WIPO 56. WO 96/33978 WIPO WO 96/33979 October 31, 1996 57. WIPO WO 96/33980 October 31, 1996 58. WIPO 59. WO 96/33981 October 31, 1996 WIPO WO 96/39145 December 12, 1996 60. January 30, 1997 WIPO 61. WO 97/03069 WO 97/06138 February 20, 1997 WIPO <del>62.</del> WIPO May 29, 1997 WO 97/18813 63. WIPO WO 97/22596 June 26, 1997 64. WIPO WO 97/28/28 August 7, 1997 65. WIPO WO 97/20034 August 21, 1997 66. WIPO WO 9//30035 August 21, 1997 67. WIPO WO 97/30044 August 21, 1997 68. OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.) Date Considered Examiner Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation in conformance and not considered. Include copy of this form with next communication to applicant.

Page 2 of 5

## Application No. Attorney Docket No. 10/573,090 056291-5241 INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) Applicants: HENNEQUIN et al. Ogrrection of PTO Form 1449 Group Art Unit: Unassigned Filing Date: March 15, 2006 Siled September 1, 2006 U.S. PATENT DOCUMENTS Class Sub-Class **Filing Date** Document No. Name Initial Date FOREIGN PATENT DOCUMENTS Translation Sub-Class Country Class Document No Date WO 97/32856 September 12, 1997 WIPO 69. WIPO 70. WO 97/38983 October 23, 1997 WIPO WO 97/38994 October 23, 1997 71. WIPO 72. WO 98/02434 January 22, 1998 April 2, 1998 WIPO 73. WO 98/13354 WIPO September 11, 1998 74. WO 98/38984 WIPO 75. WO 99/06378 February 11, 1999 July 13, 1999 WIPO WO 99/35132 76. US 6,200,976 October 28, 1999 WIPO 77. WO 99/54313 WIPO March 2, 2000 78. WO 00/10981 WIF O March 9, 2000 79. WO 00/12497 WIPO 80. WO 00/18740 April 6, 2000 WIPO WO 00/20402 April 13, 2000 81. WIPO April 20, 2000 82. WO 00/21955 WIPO 83. WO 00/24718 May 4, 2000 June 2, 2000 WIPO 84. WO 00/31048 WIPO WO 00/44728 August 3, 2000 85 WIPO WO 00/47212 August 17, 2000 86. WPO September 8, 2000 WO 00/51991 87. WIPO WO 00/55141 September 21, 2000 88. September 28, 2000 WIPO WO 00/56720 89. US 20020169180 WIPO December 28, 2000 90. WO 00/78735 WIPO February 1, 2001 91. WO 01/07432 March 22, 2001 WIPO WO 01/19788 92. WIPO 93. WO 01/21594 March 29, 2001 94. WO 01/21595 March 29, 2001 WIPO March 29, 2001 WIPO 95. WO 01/21596 March 29, 2001 WIPO WO 01/21597 96. WIPO WO 01/32651 May 10, 2001 97. WIPO WO 01/7708 October 18, 2001 98. WO 01/94241 WIPO 99. December 13, 2001 December 27, 2001 WIPO WO 01/9/8277 100. WIPO February 28, 2002 WO 02/16352 101. US 20020082271 March 7, 2002 WIPO WQ 02/18351 102. OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.) Date Considered Examiner Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Page 3 of 5

## Application No. Attorney Docket No. 10/573,090 056291-5241 INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) Applicants: HENNEQUIN et al. grrection of PTO Form 1449 Group Art Unit Unassigned Filing Date: March 15, 2006 filed September 1, 2006 **U.S. PATENT DOCUMENTS** Sub-Class Filing Date Class Initial Document No. Date Name FOREIGN PATENT DOCUMENTS Syrb-Class Translation Country Class Document No. Date US 20020082270 March 7, 2002 WIPO 103. WO 02/18370 US 6,617,329 104. WO 02/18372 March 7, 2002 WIPO US 6,653,305 WO 02/18373 WIPO 105. March 7, 2002 US 6,740,651 WIPO WO 02/18376 March 7, 2002 106. WIPO WO 02/24684 March 28, 2002 107. April 18, 2002 WIPO 108. WO 02/30924 109. WO 02/34744 Ma 2, 2002 WIPO WIPO May 30, 2002 WO 02/41882 110. WIPO WO 02/44166 June 6, 2002 111. WIPO June 20, 2002 112. WO 02/48117 US 20020173509 WI O WO 02/50043 June 27, 2002 113. July 25, 2002 WIPO WO 02/056882 114. EP 1 369 418 WIPO 115. WO 02/066445 August 29, 2002 WIPO WO 02/068409 September 6, 2002 116. September 19, 2002 WO 02/073235 **WIPO** 117. October 3, 2002 WIPO WO 02/076976 118. November 21, 2002 WIPO WO 02/092577 119. WIPO November 21, 2002 WO 02/092578 120. WPO December 5, 2092 121. WO 02/097490 WIPQ December 27, 2002 122. WO 02/102315 WIPO January 3, 2003 WO 03/000188 123. WO 03/031406 April 17, 2003 WIPO 124. May 15, 2003 WIPO 125. WO 03/040108 May 15, 2003 WIPO 126. WO 03/040109 une 5, 2003 WIPO WO 03/045364 127. June 5, 2003 WIPO WO 03/045395 128. WIPO June 19, 2003 129. WO 03/049740 US 20030149062 August 14, 2003 WIPO WO 03/066060 130. US 20030158196 WIPO WO 03/068264 August 21, 2003 131. US 20040048880 WO 03/082290 October 9, 2003 **WIPO** 132. WIPO WO 03/082831 October 9, 2003 133. US 20040044014 WIPO 134. WO 03/069439 October 30, 2003 US 20030225079 WO 02/094921 November 20, 2003 WIPO 135. WO/03/099276 December 4, 2003 WIPO 136. OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.) Date Considered Examiner Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation of not in conformance and not considered. Include copy of this form with next communication to applicant.

Page 4 of 5

INFORMATION DISCLOSURE CITATION				Attorney Docket No. 056291-5241			Application No. 10/573,090		
(Use several sheets if necessary)				Applicants: HENNEQUIN et al.					
Correction of PTO Form 1449 illed September 1, 2006				Filing Date: March 15, 2006			Group Art Unit; Unassigned		
					T DOCUMENTS				
Initial	· · · ·	Document No.	Date		Name	Class	Sub-Class	Filing Date	
Illitiai		Document No.	Date	$\dashv$	1101110	Cinos		<u> </u>	
	-								
					· · · · · · · · · · · · · · · · · · ·				
	<u> </u>		FOREIGN	PAT	ENT DOCUMENTS		/		
		Document No.	Date		Country	Class	Sub-Class	Translation	
	137.	WO 03/101491	Recember 11, 200	)3	WIPO			US 20050148607	
	138.	WO 2004/006846	January 22, 2004		WIPO				
	139.	WO 2004/064718	August 5, 2004		WIPO				
	140.	WO 2004/096226	November 11, 200	)4	WIPO		<u> </u>		
	141.	WO 2005/013998	February 17, 200:		WIPO		1		
	142.	WO 2005/026156	March 24, 2005		WIPO /				
	143.	WO 2005/026157	March 24, 2005		WIPO				
	144.	WO 2005/030757	April 7, 2003		w <b>y</b> o				
	145.	WO 2005/030765	April 7, 2005		y PO				
	146.	WO 2005/075439	August 18, 2005		WIPO		ļ		
	<u></u>	<u> </u>	<u> </u>		\	<u> </u>			
		OTHED DO	OCUMENTS (Include	lina	Author, Title, Date, Per	tinent Pa	nes etc )		
	147	Gaul et al "Discovery	and Riological Evalu	natio	of Potent Dual ErB-2/E	GFR tyros	sine Kinase l	nhibitors:6-	
					Chemistry Letters 13: 637				
	148.	Hennequin et al. "Des	ign and structure-act	vity i	relationship of a new class	s of poten	t VEGF rece	ptor tyrosine kinase	
	140	Hennequin et al "Nos	vel 4 anilinoquinazoli	nec v	vith C-7 basic side chains	· Design	and structure	activity relationship of	
	149.	a series of notent oral	lly active VEGE rece	ntor 1	tyrosine kinase inhibitors'	' Journal (	Of Medicina	1 Chemistry 45(6):1300-	
		1312 (2002)	1, 401.10, 1951.100	Pio.					
L	150.	Smaill et al. "Tyrosine	e kinase Lahibitors, 17	. Irre	eversible Inhibitors of the	Epiderma	l Growth Fa	ctor Receptor: 4-	
		(phenylamino)quinazo	oline- and 4-(phenylar	mino	0pyrido[3,2-d]pyrimidine	6-acrylai	nides bearin	g additional solubilizing	
	1	function" Journal of M	Mediomal Chemistry 4	3(7):	:1380-1397 (2000)		•		
					h Factor Receptor Kinase 7(48):46265-46272 (2002		Alone and in	Complex with a 4-	
					in cancer treatment" Exp.		er. Patents 7	(6):571-588 (1997)	
-	153.	Traxler et al. "Typosin (1998)	ne kinase inhibitors in	canc	er treatment (Part II)" Ex	p. Opin. T	her. Patents	8(12):1599-1625	
<del></del>	154.	Tsou et al. "6 Substituted-4-(3-bromophenylamino)quinazolines as Putative Irreversible Inhibitors of the Epidermal Growth Factor Receptor (EGFR) and Human Epidermal Growth Factor Receptor (HER-2) Syrosine Kinases with							
	1	Enhanced Antitumor	Activity" J. Med. Che	m. 4	4:2719-2734 (2001)				
			of EGFR kinase inhibi Chem. 11(21):4643-46		a ligand-based approach a 2003)	and its co	nfirmation w	An structure-based	
	/	<b></b>						<del></del>	
Evansina		L	Date C	`ora:	dered				
Examiner	/						• • •		
					is in conformance with Mext communication to app		draw line th	rough citation in not in	

Page 5 of 5